Navigation Links
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
Date:4/30/2009

BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR 100th Annual Meeting 2009 in Denver. "This research represents a significant advancement in the treatment of Triple Negative Breast Cancer, one of the most aggressive forms of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris.

Sponsored by Tigris, the research was led by Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Barbara Ann Karmanos Cancer Institute and professor of Pharmacology at Wayne State University School of Medicine in Detroit. The research found that the luminal (ER-positive) and the triple negative (ER, PR, and HER-2 negative) breast cancer cell lines with the basal A gene profile subtype were very sensitive to AFP-464, while the triple negative cell lines with the basal B subtype were not. However, when the latter was pre-treated with a histone deacetylase inhibitor, such as the suberoylanilide hydroxamic acid (SAHA), also known as vorinostat (Zolinza(R), Merck & Co. Inc.), the cells became very sensitive to AFP-464. The mechanism in which this is achieved is believed to be the de-silencing of ER expression by the histone deacetylase inhibitor, followed by CYP1A1 induction and subsequent AFP metabolism into active species that covalently bind to DNA in these cancer cells and cause specific cell death.

Dr. Burger said the findings offer particular hope to those women battling triple-negative breast cancer. "We could now find a way to treat every kind of invasive, metastatic breast cancer, the ER-positive and ER-negative types with AFP-464," said Dr. Burger. "The synergism between AFP-464 and vorinostat in the triple negative breast cancer cell lines is very impressive."

'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. Tigris Pharmaceuticals Files IND Application for GGTI-2418
3. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
4. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
7. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
8. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Mass. (PRWEB) March 03, 2015 Cambridge ... by Semantic Web technology, today announced that it has ... Companies That Matter in Knowledge Management.’ , To ... group of colleagues, analysts and system integrators who identify ... delivery of the right information to the right people ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qcdj5m/rnai ) ... "RNAi - Technologies, Markets and Companies" to ... ability to silence any gene once the sequence is ... to discriminate gene function. After the genome of an ... every gene in the genome and target for specific ...
(Date:3/3/2015)... SAN FRANCISCO , March 3, 2015  Johnson ... JLABS @ South San Francisco (JLABS ... Point Boulevard, South San Francisco, Calif. ... can accommodate up to 50 startups from across the ... digital health.  The first resident startups ...
(Date:3/3/2015)... DNA Diagnostics Center (DDC), one of the largest ... 20 th anniversary today. Headed by President and ... services company that focuses on DNA testing across multiple ... generates a significant portion of sales across international markets ... Peter Vitulli acknowledges the anniversary of the ...
Breaking Biology Technology:Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3
... Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that ... clinical trial to investigate the use of REOLYSIN(R) for patients with ... James Markert , Division Director of Neurosurgery, and Professor, Neurosurgery and ... , , ...
... Moffitt Cancer Center announces steadily growing interest in the ERCC1 ... Lung Cancer patients.  Each year, more than 200,000 Americans are diagnosed ... , ... response to cisplatin-based chemotherapy.   The correlation between ERCC1 levels and ...
... ... databases with the launching of PrescriberPRO@Home. This Database will allow marketers to send targeted ... or email address. , ... (Vocus) April 23, 2010 -- Healthcare Data Solutions (HDS) has recently ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial 2Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 2Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 4Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home. 2Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home. 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... frontier for pharmaceutical makers. Even after they discover a ... wonder drug, however, they have to confront a long-standing ... in a highly pure state. Now, a multi-institutional research ... Standards and Technology (NIST) may have found* a new ...
... polluting industrial processes can be made safer with enzymes. ... available for the chemical industry. , Recently a group ... of Copenhagen succeeded in producing an artificial enzyme that ... , With their group leader, Professor Mikael Bols, Ph.d. ...
... TORONTO, October 22, 2009 New research shows that ... a premature death unless they perform an adequate courtship ... research shows that "sneaker" males can slip by and ... first suitor. Scientists at the University of ...
Cached Biology News:Biochemical 'on-switch' could solve protein purification challenge 2New artificial enzyme safer for nature 2Male Australian redback spiders employ courtship strategies to preserve their life 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
... An N-nitroso-containing diabetogenic compound that acts ... pancreatic islets. An antibiotic effective against ... DNA strand breaks in pancreatic islet ... in H 2 O. RTECS LZ5775000, ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
... The pACHLT-A-BFP Baculovirus Transfer Vector is a derivative ... the gene for blue fluorescent protein (BFP), followed ... site (MCS).,Foreign genes are expressed as BFP-6xHis fusion ... restriction enzyme,sites (EcoR I, Stu I, Sac I, ...
Biology Products: